Journal
BONE MARROW TRANSPLANTATION
Volume 55, Issue 5, Pages 906-917Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41409-019-0748-1
Keywords
-
Categories
Funding
- Public Health Service Grant/Cooperative Agreement from the National Cancer Institute (NCI) [5U24-CA076518]
- National Heart, Lung and Blood Institute (NHLBI) [5U24-CA076518, 5U10-HL069294]
- National Institute of Allergy and Infectious Diseases (NIAID) [5U24-CA076518]
- Health Resources and Services Administration (HRSA/DHHS) [HHSH250201200016C]
- Office of Naval Research [N00014-15-10848, N00014-16-1-2020]
- Alexion
- Amgen, Inc.
- Astellas Pharma US
- AstraZeneca
- Be the Match Foundation
- Bluebird Bio, Inc.
- Bristol Myers Squibb Oncology
- Celgene Corporation
- Cellular Dynamics International, Inc.
- Chimerix, Inc.
- Fred Hutchinson Cancer Research Center
- Gamida Cell Ltd.
- Genentech, Inc.
- Genzyme Corporation
- Gilead Sciences, Inc.
- Health Research, Inc.
- Roswell Park Cancer Institute
- HistoGenetics, Inc.
- Incyte Corporation
- Janssen Scientific Affairs, LLC
- Jazz Pharmaceuticals, Inc.
- Jeff Gordon Children's Foundation
- The Leukemia & Lymphoma Society
- Medac, GmbH
- MedImmune
- The Medical College of Wisconsin
- Merck Co, Inc.
- Mesoblast
- MesoScale Diagnostics, Inc.
- Miltenyi Biotec, Inc.
- National Marrow Donor Program
- Neovii Biotech NA, Inc.
- Novartis Pharmaceuticals Corporation
- Onyx Pharmaceuticals
- Optum Healthcare Solutions, Inc.
- Otsuka America Pharmaceutical, Inc.
- Otsuka Pharmaceutical Co, Ltd. -Japan
- PCORI
- PerkinElmer, Inc.
- Pfizer, Inc
- Sanofi US
- Seattle Genetics
- Spectrum Pharmaceuticals, Inc.
- St. Baldrick's Foundation
- Sunesis Pharmaceuticals, Inc.
- Swedish Orphan Biovitrum, Inc.
- Takeda Oncology
- Telomere Diagnostics, Inc.
- University of Minnesota
- Wellpoint, Inc.
Ask authors/readers for more resources
Allogeneic hematopoietic cell transplantation (alloHCT) is a highly specialized procedure. We surveyed adult transplant centers in the United States (US) and then used data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) (2008-2010) to evaluate associations of center volume, infrastructure, and care delivery models with survival post alloHCT. Based on their 2010 alloHCT volume, centers were categorized as low-volume (<= 40 alloHCTs; N = 42 centers, 1900 recipients) or high-volume (>40 alloHCTs; N = 41 centers, 9637 recipients). 100-day survival was 86% (95% CI, 85-87%) in high-volume compared with 83% (95% CI, 81-85%) in low-volume centers (difference 3%; P < 0.001). One-year survival was 62% (95% CI, 61-63%) and 56% (95% CI, 54-58%), respectively (difference 6%; P < 0.001). Logistic regression analyses adjusted for patient and center characteristics; alloHCT at high-volume centers (odds ratio [OR] 1.32; P < 0.001) and presence of a survivorship program dedicated to HCT recipients (OR 1.23; P = 0.009) were associated with favorable 1-year survival compared to low-volume centers. Similar findings were observed in a CIBMTR validation cohort (2012-2014); high-volume centers had better 1-year survival (OR 1.24, P < 0.001). Among US adult transplant centers, alloHCT at high-volume centers and at centers with survivorship programs is associated with higher 1-year survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available